In the same way ACE inhibitors and Angiotensin Receptor Blockers (ARBs), which seem to reduce insulin-resistance and give some advantages in NAFLD [1], were more frequently used in FLI ≥ 60. Here, ACE is linked to metabolic dysfunction-associated steatotic liver disease.